Study: Patent law is good for big pharma because it has no innovators

Featured Story

Study: Patent law is good for big pharma because it has no innovators

July 13, 2014 6:00 am by | 0 Comments

A new study adds some empirical firepower to the idea that poor patent laws are crushing innovation in the technology industry. Researchers from the London School of Economics studied citations…


Europe backs new leukemia drugs from J&J, Gilead

Europe backs new leukemia drugs from J&J, Gilead

July 25, 2014 1:29 pm by | 0 Comments

By Reuters Staff LONDON (Reuters) – Two new leukemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal…


Over-the-counter Flonase will soon be available as GSK scores new FDA approval

Over-the-counter Flonase will soon be available as GSK scores new FDA approval

July 25, 2014 1:16 pm by | 0 Comments

Healthcare company GlaxoSmithKline (LSE:GSK)(NYSE:GSK) reported on Thursday the receipt of the US Food and Drug Administration (FDA) approval for Flonase Allergy Relief (fluticasone propionate 50 mcg spray) as an over-the-counter…



EU regulators follow FDA in recommending expanded approval of Allergan eye drug

EU regulators follow FDA in recommending expanded approval of Allergan eye drug

July 25, 2014 12:52 pm by | 0 Comments

By Reuters Staff (Reuters) – Allergan Inc, known best for its Botox wrinkle treatment, said on Friday that European Union regulators had recommended use of its eye drug Ozurdex be…


Bayer/Amgen breast cancer drug fails to delay disease progression in late-stage trial

Bayer/Amgen breast cancer drug fails to delay disease progression in late-stage trial

July 25, 2014 11:48 am by | 0 Comments

FRANKFURT (Reuters) – German drugmaker Bayer said a Phase III trial of cancer drug Nexavar in patients with advanced breast cancer did not meet its primary endpoint of delaying the…


How a computational model could make testing new breast cancer treatments cheaper & faster

How a computational model could make testing new breast cancer treatments cheaper & faster

July 25, 2014 9:45 am by | 0 Comments

Scientists waging war against breast cancer have a new reason to smile. Researchers at Lawrence Berkeley National Laboratory and Carnegie Mellon University have developed a sophisticated computational method to determine…


Novo anticipates once-daily injection for diabetes will hit the European market next year

Novo anticipates once-daily injection for diabetes will hit the European market next year

July 25, 2014 9:11 am by | 0 Comments

COPENHAGEN (Reuters) – Novo Nordisk, the world’s largest insulin maker, said on Friday it expected European Commission marketing authorization for its new two-in-one insulin drug within three months after an…


EU agency recommends approval of Novo’s insulin + type 2 diabetes treatment combo

EU agency recommends approval of Novo’s insulin + type 2 diabetes treatment combo

July 25, 2014 8:58 am by | 0 Comments

LONDON (Reuters) – A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost…



In pivotal trial, Keryx drug boosts phosphorus, iron in kidney disease patients on dialysis

In pivotal trial, Keryx drug boosts phosphorus, iron in kidney disease patients on dialysis

July 24, 2014 8:19 pm by | 0 Comments

(Reuters) – A pivotal trial of Keryx Biopharmaceuticals Inc’s experimental drug Zerenex showed that it improved levels of serum phosphorus and iron in patients on kidney dialysis, according to results…


7 healthcare and life sciences projects get love from Maryland in $6.5 million innovation initiative

7 healthcare and life sciences projects get love from Maryland in $6.5 million innovation initiative

July 24, 2014 6:52 pm by | 0 Comments

As part of 1-year-old Maryland Innovation Initiative by Maryland’s Technology Development Corporation to help advance university research and support early-stage companies, 67 commercialization projects and startup companies received $6.4 million. Early-stage…


Incyte misses goals in late-stage study of bone marrow disorder drug

Incyte misses goals in late-stage study of bone marrow disorder drug

July 24, 2014 4:02 pm by | 0 Comments

M2PHARMA-July 24, 2014-Incyte’s Phase III study of ruxolitinib in polycythemia vera misses primary endpoint (C)2014 M2 COMMUNICATIONS http://www.m2.com24 July 2014 – US Incyte Corporation (NASDAQ:INCY) said yesterday that a Phase…


Gilead partners with MPP to give poor countries access to experimental HIV, hepatitis B drug

Gilead partners with MPP to give poor countries access to experimental HIV, hepatitis B drug

July 24, 2014 4:00 pm by | 0 Comments

Biopharmaceutical company Gilead Sciences (NasdaqGS:GILD) on Thursday launched a new agreement to expand access to its investigational drug tenofovir alafenamide (TAF) for HIV and hepatitis B, contingent on the medicine’s…


FDA grants orphan drug status to experimental treatment for ‘stone man syndrome’

FDA grants orphan drug status to experimental treatment for ‘stone man syndrome’

July 24, 2014 3:50 pm by | 0 Comments

Canadian Clementia Pharmaceuticals Inc said Thursday that palovarotene, its lead product candidate, had received orphan drug status from the US FDA as a therapy of Fibrodysplasia Ossificans Progressiva (FOP), a…


Lancet study: Popular pain medicine paracetamol doesn’t actually work on back pain

Lancet study: Popular pain medicine paracetamol doesn’t actually work on back pain

July 24, 2014 2:18 pm by | 0 Comments

LONDON (Reuters) – Paracetamol, a painkiller universally recommended to treat people with acute low back pain, does not speed recovery or reduce pain from the condition, according to the results…


Amgen has grand plans for Brazil, where the biotech has seen a big boost in revenue this year

Amgen has grand plans for Brazil, where the biotech has seen a big boost in revenue this year

July 24, 2014 12:40 pm by | 0 Comments

SAO PAULO (Reuters) – Amgen Inc, the world’s biggest biotechnology company, has had a surge in sales in Brazil this year and it plans to double its drug portfolio in…


FDA paves way for Novartis to market biosimilar of Amgen’s Neupogen in U.S.

FDA paves way for Novartis to market biosimilar of Amgen’s Neupogen in U.S.

July 24, 2014 10:46 am by | 0 Comments

(Reuters) – U.S. regulators have accepted an application by Sandoz – the generics arm of Novartis – seeking approval for a copycat version of Amgen’s drug Neupogen, or filgrastim, for…